辛伐他汀联合非诺贝特治疗混合性高脂血症的疗效观察  

Observation of the curative effect on simvastatin combining with fenofibrate treatment for combined hyperlipidemia

作　　者：李勇[1] 陈富荣[2] 黄景文[3] 

机构地区：[1]广东省佛山市禅城区张槎医院心内科,广东佛山528000 [2]广东省人民医院心内科,广东广州510080 [3]广东省佛山市南海区人民医院心内科,广东佛山528200

出　　处：《中国医药科学》2012年第2期17-19,共3页China Medicine And Pharmacy

摘　　要：目的探讨辛伐他汀联合非诺贝特治疗混合性高脂血症的疗效及安全性。方法将146例混合性高脂血症患者随机分为两组,对照组73例给予辛伐他汀治疗,观察组73例在对照组的基础上加用非诺贝特,4周为1个疗程,观察两组患者降脂的疗效及不良反应发生情况。结果观察组临床效果总有效率为95.89%,对照组为78.08%(P<0.05);治疗后两组的TC、TG、LDL-C及HDL-C水平的变化均有显著性改善(P<0.05或P<0.01),但观察组的TG、LDL-C的改善情况优于对照组(P<0.05);观察组TC、TG、LDL-C的达标率分别为58.90%、45.21%、50.68%,3项达标率为36.99%,明显高于对照组的13.70%(P<0.05);两组总不良反应发生率比较差异无统计学意义(P>0.05)。结论辛伐他汀联合非诺贝特治疗混合性高脂血症可充分发挥药物互补、协同作用,有利于全面调节血脂异常,提高血脂水平的达标率,减少不良反应。Objective To investigate the clinical effect and the safety of the curative effect on simvastatin combining with fenofibrate treatment for combined hyperlipidemia. Methods 146 patients with combined hyperlipidemia were randomly divided into two groups, 73 cases in the control group were treated by simvastatin, and on the basis of the control group, the observation group was treated by fenofibrate,4 weeks for one course of the treatment, observed the effect of decreasing blood fat and untoward effect. Results On the clinical effects, the total effective rate of the observation group was 95.89%, and the control group was 78.08%, had different statistical significance. The change of the TC, TG, LDL-C and HDL-C level in two groups were changed more than before , there were different statistical significance between post-treatment and pretherapy, and the TC, TG and LDL-C level of the observation group was changed more than the control group, there were different statistical significance between the observation group and the control group, and the TC, TG, LDL-C of the achievement ratio in the observation group were 58.90%/45.21% and 50.68%, the achievement ratio of the observation group was 36.99%,it was higher than the 13.70% of the control group, there were different statistical significance. The untoward effect in two groups had no statistical significance. Conclusion The combined hyperlipidemia is treated by simvastatin and fenofibrate,it can adequately bring the druggery complementation into play and coordination, it is good for regulating the dyslipidemia all sidedly,improvin~ the achievement ratio of blood lipid level, decreasing the untoward effect.

关 键 词：混合性高脂血症 辛伐他汀 非诺贝特 

分 类 号：R589.2[医药卫生—内分泌]